Literature DB >> 30500303

Application of advanced MRI techniques to monitor pharmacologic and rehabilitative treatment in multiple sclerosis: current status and future perspectives.

Maria A Rocca1,2, Paolo Preziosa1, Massimo Filippi1,2.   

Abstract

Introduction: Advances in magnetic resonance imaging (MRI) technology and analyses are improving our understanding of the pathophysiology of multiple sclerosis (MS). Due to their ability to grade the presence of irreversible tissue loss, microstructural tissue abnormalities, metabolic changes and functional plasticity, the application of these techniques is also expanding our knowledge on the efficacy and mechanisms of action of different pharmacological and rehabilitative treatments. Areas covered: This review discusses recent findings derived from the application of advanced MRI techniques to evaluate the structural and functional substrates underlying the effects of pharmacologic and rehabilitative treatments in patients with MS. Current applications as outcome in clinical trials and observational studies, their interpretation and possible pitfalls in their use are discussed. Finally, how these techniques could evolve in the future to improve monitoring of disease progression and treatment response is examined. Expert commentary: The number of treatments currently available for MS is increasing. The application of advanced MRI techniques is providing reliable and specific measures to better understand the targets of different treatments, including neuroprotection, tissue repair, and brain plasticity. This is a fundamental progress to move toward personalized medicine and individual treatment selection.

Entities:  

Keywords:  Disease modifying treatments; magnetic resonance imaging; multiple sclerosis; rehabilitation; treatment monitoring

Mesh:

Year:  2018        PMID: 30500303     DOI: 10.1080/14737175.2019.1555038

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  4 in total

1.  Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers.

Authors:  Monica Margoni; Paolo Preziosa; Paola Tortorella; Massimo Filippi; Maria A Rocca
Journal:  Neurotherapeutics       Date:  2022-06-06       Impact factor: 6.088

2.  Mapping brain structure and function in professional fencers: A model to study training effects on central nervous system plasticity.

Authors:  Claudio Cordani; Paolo Preziosa; Roberto Gatti; Carlotta Castellani; Massimo Filippi; Maria Assunta Rocca
Journal:  Hum Brain Mapp       Date:  2022-04-01       Impact factor: 5.399

3.  Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion.

Authors:  Massimo Filippi; Maria Pia Amato; Diego Centonze; Paolo Gallo; Claudio Gasperini; Matilde Inglese; Francesco Patti; Carlo Pozzilli; Paolo Preziosa; Maria Trojano
Journal:  J Neurol       Date:  2022-05-24       Impact factor: 6.682

4.  No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis.

Authors:  Claudia Piervincenzi; Emilia Sbardella; Marta Altieri; Antonio Ianniello; Patrizia Pantano; Carlo Pozzilli; Nikolaos Petsas
Journal:  Neurol Ther       Date:  2022-02-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.